Enroll in a Study

Triple Negative Breast Cancer

CURRENT

Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC

A clinical trial for patients with CCR5+ mTNBC. Patients must be recently diagnosed with metastatic disease and treatment naive in the metastatic setting. Due to COVD-19, it is currently difficult to enroll out of town patients. We can still begin the prescreen process and are hopeful to open enrollment as soon as possible.

 

Hep B Treatment

CURRENT

A Phase II study in treatment naïve, Chronic Hep B Patients, 72 week treatment phase and 24 week follow up. (Open for screening on May 2nd 2020.)

 

Fatty Liver

CURRENT

Multiple clinical trials studying investigational oral medicine for the treatment of Fatty Liver Disease. Fatty Liver Disease is also known as NASH (Non-alcoholic Steatohepatitis). Compensation may be available for time and travel.  

 

Este ensayo clínico está estudiando un medicamento oral en investigación para el tratamiento de la enfermedad del hígado graso. La enfermedad del hígado graso también se conoce como "NASH" (esteatohepatitis no alcohólica) en Inglés. La compensación puede estar disponible por tiempo y viaje.

 

Solid Tumor

CURRENT

CD09 BASKET: Basket Study of Leronlimab (PRO 140) in Patients with CCR5+ Locally Advanced or Metastatic Solid Tumors

 

The study treatment, Leronlimab (PRO 140), is a once per week subcutaneous injection. It is not a monotherapy, and is used along with one’s current cancer treatment for their locally advanced or metastatic solid tumors.

Subjects must provide 5 unstained slides from a previous biopsy of either their primary tumor or a metastases to be tested for CCR5.

Ongoing Studies

 

HIV Cure

NOT CURRENTLY ENROLLING

Ongoing HIV cure gene therapy research studies (14 years).

On hold due to Covid-19 restrictions.

 

Hep B Treatment

NOT CURRENTLY ENROLLING

A clinical trial for patients with Hepatitis B with Enanta and Vir.  

On hold due to Covid-19 restrictions.

 

HIV Research

NOT CURRENTLY ENROLLING

Multiple cell collection for research studies with Gilead, Merck, Janssen.

On hold due to Covid-19 restrictions.

 

HIV Treatment

NOT CURRENTLY ENROLLING

Multiple research studies with Abbvie and Cytodyn.

TaiMed: A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Sequential Single Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Antiretroviral Activity of the Intravenous Administration TMB-365 in HIV-1 Infected Participants

Subjects are eligible for screening if they have not taken antiretroviral medication for 3 months. Subjects will receive one single dose of TMB-365 or placebo, and will complete a total of 13 or more visits over 2.5 months.

On hold due to Covid-19 restrictions.

Call Dr. Jay

415-353-0800

Email Dr. Jay